1. |
Güthle M, Ettrich T, Seufferlein T. Immunotherapy in gastrointestinal cancers. Visc Med, 2020, 36(3): 231-237.
|
2. |
Turkes F, Mencel J, Starling N. Targeting the immune milieu in gastrointestinal cancers. J Gastroenterol, 2020, 55(10): 909-926.
|
3. |
Barsouk A, Thandra KC, Saginala K, et al. Chemical risk factors of primary liver cancer: an update. Hepat Med, 2021, 12: 179-188.
|
4. |
Dolcetti R, De Re V, Canzonieri V. Immunotherapy for gastric cancer: time for a personalized approach? Int J Mol Sci, 2018, 19(6): 1602. doi: 10.3390/ijms19061602.
|
5. |
Sartor O, de Bono J, Chi KN, et al. Lutetium-177-PSMA-617 for metastatic castration-resistant prostate cancer. N Engl J Med, 2021, 385(12): 1091-1103.
|
6. |
Meyer C, Dahlbom M, Lindner T, et al. Radiation dosimetry and biodistribution of 68Ga-FAPI-46 PET imaging in cancer patients. J Nucl Med, 2020, 61(8): 1171-1177.
|
7. |
Fitzgerald AA, Weiner LM. The role of fibroblast activation protein in health and malignancy. Cancer Metastasis Rev, 2020, 39(3): 783-803.
|
8. |
Zboralski D, Hoehne A, Bredenbeck A, et al. Preclinical evaluation of FAP-2286 for fibroblast activation protein targeted radionuclide imaging and therapy. Eur J Nucl Med Mol Imaging, 2022, 49(11): 3651-3667.
|
9. |
Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1. 1). Eur J Cancer, 2009, 45(2): 228-247.
|
10. |
O JH, Lodge MA, Wahl RL. Practical PERCIST: a simplified guide to PET response criteria in solid tumors 1. 0. Radiology, 2016, 280(2): 576-584.
|
11. |
Kratochwil C, Flechsig P, Lindner T, et al. 68Ga-FAPI PET/CT: tracer uptake in 28 different kinds of cancer. J Nucl Med, 2019, 60(6): 801-805.
|
12. |
Li M, Younis MH, Zhang Y, et al. Clinical summary of fibroblast activation protein inhibitor-based radiopharmaceuticals: cancer and beyond. Eur J Nucl Med Mol Imaging, 2022, 49(8): 2844-2868.
|
13. |
Assadi M, Rekabpour SJ, Jafari E, et al. Feasibility and therapeutic potential of 177Lu-fibroblast activation protein inhibitor-46 for patients with relapsed or refractory cancers: a preliminary study. Clin Nucl Med, 2021, 46(11): e523-e530.
|
14. |
Kuyumcu S, Kovan B, Sanli Y, et al. Safety of fibroblast activation protein-targeted radionuclide therapy by a low-dose dosimetric approach using 177Lu-FAPI04. Clin Nucl Med, 2021, 46(8): 641-646.
|
15. |
Lindner T, Loktev A, Altmann A, et al. Development of quinoline-based theranostic ligands for the targeting of fibroblast activation protein. J Nucl Med, 2018, 59(9): 1415-1422.
|
16. |
Privé BM, Boussihmad MA, Timmermans B, et al. Fibroblast activation protein-targeted radionuclide therapy: background, opportunities, and challenges of first (pre)clinical studies. Eur J Nucl Med Mol Imaging, 2023, 50(7): 1906-1918.
|
17. |
Liu X, Li D, Ma T, et al. Autophagy inhibition improves the targeted radionuclide therapy efficacy of 131I-FAP-2286 in pancreatic cancer xenografts. J Transl Med, 2024, 22(1): 156. doi: 10.1186/s12967-024-04958-6.
|
18. |
Banihashemian SS, Akbari ME, Pirayesh E, et al. Feasibility and therapeutic potential of [177Lu]Lu-FAPI-2286 in patients with advanced metastatic sarcoma. Eur J Nucl Med Mol Imaging, 2024, 52(1): 237-246.
|
19. |
Pang Y, Zhao L, Meng T, et al. PET imaging of fibroblast activation protein in various types of cancer using 68Ga-FAP-2286: comparison with 18F-FDG and 68Ga-FAPI-46 in a single-center, prospective study. J Nucl Med, 2023, 64(3): 386-394.
|
20. |
Kline B, Yadav S, Seo Y, et al. 68Ga-FAP-2286 PET of solid tumors: biodistribution, dosimetry, and comparison with 18F-FDG. J Nucl Med, 2024, 65(6): 938-943.
|
21. |
Moris D, Palta M, Kim C, et al. Advances in the treatment of intrahepatic cholangiocarcinoma: an overview of the current and future therapeutic landscape for clinicians. CA Cancer J Clin, 2023, 73(2): 198-222.
|
22. |
Biller LH, Schrag D. Diagnosis and treatment of metastatic colorectal cancer: a review. JAMA, 2021, 325(7): 669-685.
|
23. |
Stoop TF, Javed AA, Oba A, et al. Pancreatic cancer. Lancet, 2025, 405(10485): 1182-1202.
|
24. |
Zhan T, Betge J, Schulte N, et al. Digestive cancers: mechanisms, therapeutics and management. Signal Transduct Target Ther, 2025, 10(1): 24. doi: 10.1038/s41392-024-02097-4.
|
25. |
Teng F, Kong L, Meng X, et al. Radiotherapy combined with immune checkpoint blockade immunotherapy: achievements and challenges. Cancer Lett, 2015, 365(1): 23-29.
|
26. |
Theelen WSME, Chen D, Verma V, et al. Pembrolizumab with or without radiotherapy for metastatic non-small-cell lung cancer: a pooled analysis of two randomised trials. Lancet Respir Med, 2021, 9(5): 467-475.
|
27. |
Chen J, Zhou Y, Pang Y, et al. FAP-targeted radioligand therapy with 68Ga/177Lu-DOTA-2P(FAPI)2 enhance immunogenicity and synergize with PD-L1 inhibitors for improved antitumor efficacy. J Immunother Cancer, 2025, 13(1): e010212. doi: 10.1136/jitc-2024-010212.
|
28. |
Shi J, Gao H, Wu Y, et al. Nuclear imaging of PD-L1 expression promotes the synergistic antitumor efficacy of targeted radionuclide therapy and immune checkpoint blockade. Eur J Nucl Med Mol Imaging, 2025, 52(3): 955-969.
|
29. |
Ferdinandus J, Costa PF, Kessler L, et al. Initial clinical experience with 90Y-FAPI-46 radioligand therapy for advanced-stage solid tumors: a case series of 9 patients. J Nucl Med, 2022, 63(5): 727-734.
|
30. |
Baum RP, Schuchardt C, Singh A, et al. Feasibility, biodistribution, and preliminary dosimetry in peptide-targeted radionuclide therapy of diverse adenocarcinomas using 177Lu-FAP-2286: first-in-humans results. J Nucl Med, 2022, 63(3): 415-423.
|